David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

Case 1:09-cv-04665-DLC Document 49-2 Filed 03/30/2010 Page 27 of 45Patent Nos. 5,965,584 and 6,329,404 in connection with Teva’s ANDA to sell a generic version ofActos ® , which ANDA uses NDA 21-073 as the reference listed drug.JURISDICTION AND VENUE10. This counterclaim arises under the Federal Food, Drug, and Cosmetics Act,specifically 21 U.S.C. § 355(j)(5)(C)(ii). Subject matter jurisdiction exists pursuant to 28 U.S.C.§§ 1331 and 1338.11. Personal jurisdiction is proper over Takeda, as Takeda availed itself of thejurisdiction of this Court by filing the patent infringement action in which these counterclaims arebeing asserted.12. Venue is proper in this Court, as the statute authorizing this counterclaim, 21 U.S.C.§ 355(j)(5)(C)(ii), provides that the cause of action it creates can only be brought as a counterclaimin this patent infringement action.FACTUAL BACKGROUNDRequirements for Listing Patent Information in the Orange Book13. Part of the regulatory structure created by the Hatch-Waxman Act involves aprocess for identifying and addressing patents that arguably apply to brand and generic drugproducts. Generally speaking, the regulatory structure requires the holder of an NDA to submitinformation concerning certain patents to the FDA. FDA incorporates that information into adatabase called “Approved Drug Products with Therapeutic Equivalence Evaluations,” butgenerally referred to as the “Orange Book.” Patent information is organized in the Orange Book bybeing listed for one or more specific NDAs. Then, when a company seeks to file an ANDA, itmust submit certain patent certifications or statements, described more fully below, to each patentthat is listed in the Orange Book for the NDA that is the reference listed drug for the ANDA.9067383.126